Ellipses Pharma features in the Guardian Innovations In Oncology and Imaging Series As part of The Guardian's Innovations in Oncology and Imaging series, our Chairman and Co-Founder Professor Sir Chris Evans OBE, and our CMO Professor Tobi Arkenau explain how our unique and disruptive drug development model is accelerating the development of potential new cancer [...]
Ellipses EP0031 granted Orphan Drug Designation from the US Food and Drug Administration EP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug [...]
Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor [...]
Ellipses updates clinicians at Asco on clinical trial programmes Ellipses Pharma (“Ellipses”), a global company drug development company focused on accelerating innovative cancer medicines and treatments, today announces its leadership team will attend the forthcoming American Society of Oncology (ASCO) conference in Chicago where they will brief clinicians on the progress of clinical and pre-clinical [...]
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]
Expansion of Scientific Affairs Group More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG). Ellipses [...]
Ellipses Pharma features in SCRIP Ellipses Pharma has been featured in SCRIP: READ ARTICLE About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted [...]
Ellipses updates clinicians at Asco on clinical trial programmes London, UK, 21 November 2022: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the San Antonio Breast Cancer Symposium [...]
Ellipses Pharma announces FDA approval of IND application for EP0042 for patients with acute myeloid leukaemia IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042’s ongoing phase 1/2 trial Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and [...]
Striving to improve treatment options for Acute Myeloid Leukaemia By Professor Tobias Arkenau, Global Head of Drug Development and Chief Medical Officer, Ellipses Pharma If there is one thing a cancer patient wants beyond fast, effective treatment – it is hope. Initial diagnosis is naturally frightening for patients but the realisation that their prescribed treatment [...]
